Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-03-22Clinical Trial Update: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating AMG 562 in relapsed/refractory DLBCL, MCL, or follicular lymphoma was terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-13Clinical Trial Update: Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL [Phase 2]
Phase 2 clinical trial evaluating zanubrutinib, lenalidomide, and R-ICE in relapsed/refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma [Phase 1, Phase 2]
Clinical trial of mocetinostat in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2024-03-07Clinical Trial Update: Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma [Phase 3]
Phase 3 study evaluating axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory diffuse large B-cell lymphoma has co…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI [Phase 2]
Phase 2 trial evaluating orelabrutinib combined with R-CDOP for high CNS-relapse risk DLBCL patients (CNS-IPI defined).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-03-01Clinical Trial Update: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma [Phase 2]
This Phase 2 trial evaluating NIR178 in combination with PDR001 across multiple solid tumors and non-Hodgkin lymphoma was terminated, with r…
-
CLINICAL_TRIALS trial_result · 2024-02-26Clinical Trial Update: Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb [Phase 2]
Phase 2 trial comparing R-COMP to R-CHOP in newly diagnosed non-localised DLBCL and Follicular Lymphoma Grade IIIb has completed.
-
CLINICAL_TRIALS trial_result · 2024-02-20Clinical Trial Update: A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients [Phase 3]
Phase 3 trial comparing G-CHOP to R-CHOP in untreated diffuse large B-cell lymphoma (DLBCL) with unknown status.
-
CLINICAL_TRIALS trial_result · 2024-02-08Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 2]
Phase 2 clinical trial update for mitoxantrone hydrochloride liposome injection in relapsed/refractory diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma [Phase 3]
Phase 3 study evaluating Orelabrutinib plus R-CHOP in treatment-naïve patients with the MCD subtype of diffuse large B-cell lymphoma (DLBCL)…
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating loncastuximab tesirine in combination with ibrutinib for diffuse large B-cell lymphoma and mantle cell lymphoma w…
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. [Phase 1]
Phase 1 study of pembrolizumab plus vorinostat in relapsed or refractory B-cell lymphomas and classic Hodgkin lymphoma; results posted in Fe…
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma [Phase 2]
A Phase 2 study evaluating the combination of copanlisib and nivolumab in patients with recurrent or refractory diffuse large B-cell lymphom…
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL [Phase 1, Phase 2]
Phase 1/2 trial update for CX-2029 in solid tumors and DLBCL completed; aims to identify safe and active dose levels.
-
CLINICAL_TRIALS trial_result · 2024-01-16Clinical Trial Update: Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) [Phase 1]
A Phase 1 study of Betalutin in relapsed or refractory diffuse large B-cell lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 trial update evaluating ibrutinib in combination with standard immuno-chemotherapy in younger, high-risk adults with diffuse large B…
-
CLINICAL_TRIALS trial_result · 2024-01-05Clinical Trial Update: Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL [Phase 2]
Phase 2 trial update investigating copanlisib with rituximab and CHOP for previously untreated diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2024-01-02Clinical Trial Update: CD30 Imaging in Diffuse Large B-cell Lymphoma [Phase 3]
Phase 3 clinical trial update on CD30 imaging in diffuse large B-cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-12-27Clinical Trial Update: A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL [Phase 3]
A Phase 3 trial comparing SIBP-02 + Rituximab + CHOP versus a reference regimen in previously untreated CD20+ diffuse large B-cell lymphoma …
-
CLINICAL_TRIALS trial_result · 2023-12-26Clinical Trial Update: A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 1, Phase 2]
Phase 1/2 trial evaluating obinutuzumab, polatuzumab vedotin, and lenalidomide in relapsed or refractory follicular lymphoma and rituximab w…
-
CLINICAL_TRIALS trial_result · 2023-12-14Clinical Trial Update: Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients [Phase 1, Phase 2]
Phase 1/2 trial evaluating selinexor with R-CHOP followed by selinexor maintenance for untreated EBV-positive diffuse large B-cell lymphoma.…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) [Phase 2]
Phase 2 safety trial evaluating lisocabtagene maraleucel (JCAR017) for relapsed/refractory B-cell non-Hodgkin lymphoma in the outpatient set…
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas [Phase 2]
Phase 2 trial of pembrolizumab in relapsed/refractory gray-zone lymphoma, primary CNS lymphoma, and other extranodal diffuse large B-cell ly…
-
CLINICAL_TRIALS trial_result · 2023-11-24Clinical Trial Update: CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma [Phase 2]
Phase 2 trial update for CD19-targeted CAR T cells in relapsed/refractory non-Hodgkin lymphoma, including DLBCL and follicular lymphoma, wit…
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: DPX-Survivac and Checkpoint Inhibitor in DLBCL [Phase 2]
Phase 2 clinical trial update evaluating DPX-Survivac in combination with a checkpoint inhibitor for adult diffuse large B-cell lymphoma (DL…